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An historical account is presented of attempts to establish the serologic identity of Lister's
pneumococcal capsular Groups T and V.
Intimations of the serologic diversity of pneumococci, isolated independently in
1880 by Sternberg and by Pasteur, began to appear shortly before the end of the
nineteenth century. In June 1897, Bezanson and Griffon [1], attempting to devise
an analogue of the Widal test to be used in the diagnosis ofpneumococcal infection,
described the pneumococcal agglutinating capacity of sera derived from experimen-
tally infected animals and from naturally infected humans. For their test organism,
they used a strain of pneumococcus recovered in December 1896, from the heart's
blood of a mouse inoculated with sputum from a man with pneumonia. In all,
Bezanson and Griffon studied the sera of seven patients with pneumonia. The sera
of five patients agglutinated their test strain of pneumococcus; but those of two
cases, one with a necrotizing pneumonia and the other with purulent pleurisy oflong
duration, failed to do so. The organism recovered from the case of necrotizing
pneumonia had some attributes similar to those ofpneumococcus type 3. Ofthe two
latter cases, the authors wrote: "In these two cases, the absence of the agglutinating
reaction in the serum seeded with the common pneumococcus ('le pneumocoque
vulgaire') permits us to see that, besides the common pneumococcus, there exist
some other races of pneumococcus, which, from the point ofview ofagglutination,
behave as different microbes." They concluded that these findings, plus the diffi-
culty in culturing pneumococcus, made it unlikely that serodiagnosis could be ap-
plied to the diagnosis of pneumococcal infection as it is in the diagnosis of typhoid
fever.
In the ensuing 13 years, additional observations suggesting the heterogeneity of
pneumococcal types appeared, culminating in the report of Neufeld and Handel,
which established this fact in 1910 [2]. The history of this period has been reviewed
both by White [3] and by Heffron [4].
In 1911, Sir Almroth Wright, who is usually credited with the development of
typhoid vaccine, went from England to South Africa to attempt to reduce by pro-
phylactic inoculation the ravages of pneumococcal pneumonia among gold miners
in that country [5]. Although Neufeld and Handel's report indicating the existence
173
Address reprint requests to: Robert Austrian, M.D., Department of Research Medicine, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104
Copyright © 1982 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.ROBERT AUSTRIAN
of at least two serotypes of pneumococcus had appeared the year before, there is no
indication in the publications of Wright and his colleagues that cognizance was
taken of this fact in the preparation of the pneumococcal vaccines employed in the
initial field trials. Among Wright's associates in these investigations was F. Spencer
Lister [6].
Frederick Spencer Lister was born in Nottinghamshire, England, in 1875. He was
educated in Cambridgeshire and, after attending St. Bartholomew's Hospital,
qualified as M.R.C.S. in 1905. Thereafter, he served for a time as the doctor aboard
a cable-laying ship and arrived in South Africa in 1907. Electing to remain in that
country and following a brief period in private practice, he became associated with
the mining industry. There he developed an interest in pneumonia which led to his
association with Wright when the latter came to Johannesburg. It was an association
that stimulated Lister's continuously productive investigations ofthe pneumococcus
over the ensuing quarter century.
In his early studies with Wright, Lister was struck by the infrequency with which
recently isolated strains ofpneumococci were opsonized, even with serum ofthe pa-
tient from whom they were recovered. Reasoning that serum obtained at the time of
crisis might opsonize the organism causing illness, Lister took isolates from blood or
from material obtained by lung puncture and examined the immunologic responses
in 20 cases of pneumonia meeting these criteria. Among the 14 cases which
recovered, opsonization and agglutination by the patient's serum of the pneumo-
cocci causing infection were observed in 12, whereas among the six who died, these
phenomena were noted only in two [7]. There are several explanations for the prob-
able failure to detect opsonins in the blood of most patients who died. Death may
have occurred sufficiently early in illness to have provided too little time for an-
tibodies (opsonins) to have developed; they are not usually detectable in the serum
until a week or more has elapsed following the onset of illness. Second, the patient
may have absorbed in the course of severe illness sufficient bacterial capsular an-
tigen to combine with all the antibody (opsonin) produced by the patient; free an-
tibody following recovery from pneumococcal pneumonia may not be detectable in
some patients for four to eight weeks after onset of illness.
When the isolates from 18 cases of pneumonia obtained from blood or direct
aspirates of the lung were examined systematically with each of the reactive sera, it
became quickly apparent that the organisms were serologically heterogeneous, fall-
ing into four groups which Lister designated A, B, C, and D. Lister concluded the
discussion of his findings with the following remarks:
If the validity of this method of classifying pneumococci be confirmed it
will have more than one useful application. The possibility of identifying the
particular strains ofthis organism will provide a clue as to the source ofinfec-
tion in different cases, and will help to elucidate the role ofthose pneumococ-
cal organisms which are found so commonly in the throats of healthy in-
dividuals. The prevalence of different groups of pneumococci in different
circumstances -industrial, tribal, geographical etc. -will be capable of in-
vestigation. The suggestion that second attacks of pneumonia are due to in-
vasion by another organism can be put to the test. These and many similar
enquiries may be rendered feasible.
The prophylactic pneumococcal vaccine now so extensively used on these
fields may, in the light ofthese studies become modified; it is obvious that the
efficacy ofsuch vaccine would be enhanced ifuse were made ofthe particular
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strain of organism to infection by which the labourers will be exposed. It may
also be found advantageous to use certain definite combinations of
strains. . . .
The serum therapy of pneumonia, which has not hitherto afforded notable
results, may derive additional importance when it can be used in so specific a
manner as the results of these investigations lead me to hope.
Lister's report coincided closely with one describing studies conducted in-
dependently at the Rockefeller Institute, and his text bears the following postscript:
Since committing the above to paper my attention has been drawn to some
recent work by A.R. Dochez and L.J. Gillespie and which has appeared in
the Journal of the American Medical Association for September 6th, 1913
(pages 727-730). Although these workers have adopted different methods of
investigation, yet their observations seem to have led them to conclusions
somewhat similar to my own.
Over the ensuing two decades the number of pneumococcal groups identified in
South Africa expanded gradually from the four defined in the initial report of 1913
to seven in 1916 [8], 10 in 1917 [9], 15 or 16 in 1931 [10], and 21 in 1935 [11], all
designated by capital letters. In the same period, the serotypes of pneumococci
classified originally in Dochez and Gillespie's Group IV were scrutinized in a number
of laboratories in North America and in Europe, culminating in the publications of
Cooper and her associates, who, by 1931, had recognized 33 capsular serotypes of
pneumococci [12]. It is of historical interest to note that this immunologic classifica-
tion of an encapsulated organism was accomplished without utilization of the
Quellung reaction, described originally by Neufeld in 1902 [13].
In 1938, David Ordman, an associate of Lister, published a report entitled:
"Pneumococcus Types in South Africa. A Study of their Occurrence and Distribu-
tion in the Population and the Effect Thereon of Prophylactic Inoculation" [14]. In
it, there is a reconciliation of the South African and American designations of
pneumococcal types. Of 30 American capsular types (types 26 and 30 were con-
sidered identical with types 6 and 15), all but those numbered 31 and 32 had been
recognized in South Africa. Of the 30 designated South African Groups (types), all
but Groups T and V had their counterparts in Cooper's classification. It should be
noted that pneumococci in South African Groups (types) D, F, G, H, J, L, and P
were not available for study and that supplies of antiserum to these groups had been
exhausted, so that it was no longer possible to determine their identities in other
schemes of classification. The table reconciling Lister's and Cooper's nomenclatures
may be found in Appendix B of Heffron's monograph [4].
Pneumococcal Groups T and V are cited for the first time in Lister and Ordman's
publications in 1935 [11], and the incidence of infection with the former was evi-
dently great enough to lead to its inclusion in the polyvalent whole bacterial vaccine
used for the prevention of pneumonia at that period. In Ordman's study of 879
pneumococcal isolates from unvaccinated native Africans with pneumonia, strains
of Group T ranked seventh in frequency, accounting for 1.4 percent of all isolates,
and those of Group V ranked eighth, together with types 5 and 8, each accounting
for 1.1 percent of the strains recovered. Regrettably, no data on bacteremic illness
are provided. Among 170 Europeans with pneumonia, pneumococcus Group T was
recovered from one, and there were two isolates of capsular Group V [14].
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1940s, both in Denmark and in the United States, and included studies of
unclassified strains provided to laboratories in both countries by Ordman. In 1944,
Eddy reported that pneumococci of South African capsular Group T, a strain of
which she had received from Ordman, were identical with her strain ofcapsular type
72 in the American classification [15]. Six years later, Lund, in Denmark, published
a report entitled "Four New Pneumococcus Types" among which are included
Danish capsular types 45 and 46 [16]. Of these types she wrote:
From Dr. Ordman, Johannesburg, South Africa, we have received 3
pneumococcus strains-X4803, X2368, and W5019-that all give capsular
swelling in type 45 serum.... Type 45 appears to be of rather frequent oc-
currence in South Africa, whereas it has not yet been demonstrated in Den-
mark.
Type 46
In 1938 Ordman reported the pneumococcus types found in South Africa.
In America, these types were compared with Cooper's types (1-32). For the
type designated by Ordman as "T", no corresponding type was at that time
found in the American classification given by Cooper. Subsequently, Eddy
(1944) set up "T" as type 72 (group 5).
Type "T" is of rather frequent occurrence in South Africa. Ordman found
it in 1.2% of 1496 pneumonia patients and in 1.0% of 693 patients with
pneumococcus meningitis. Strain "T" No. 378 was kindly sent us by Dr. Ord-
man who states that this strain was isolated by him in 1937 from a native
miner with pneumonia.
Type "T" is not identical with any of the 73 pneumococcus types hitherto
known in Denmark....
Lund's observations pose a curious dilemma; for, by identifying pneumococci of
South African Group (type) T with Danish capsular type 46 (American type 73), she
is associating pneumococci of Group T with a different capsular type than Eddy,
who identified them as belonging to American type 72 (Danish type 45). Comment-
ing on the discrepancy seven years later, Lund stated:
By cross-absorbtion Eddy's type 72 is found to be identical with type 45
(Lund, 1950).... The strains concerned of type 45 and Eddy 72 were all
slightly virulent for mice.
Cross-absorbtion of Eddy's type 73 shows identity with type 46 (Lund,
1950). Either strain reacts with type 44. Type 46 is identical with Type T
which was established in South Africa by Ordman (1938). Eddy is mistaken
when she declares her type 72 identical with type T (Eddy, 1944, p. 450). Type
46 (strain "T") and Eddy's strain 73 are both highly virulent for mice [17].
It is clear that there is an unreconciled disagreement between Eddy's and Lund's
classification of pneumococci of South African Group (type) T in the Danish and
American nomenclatures ofcapsular types. Interestingly, there is no mention in any
of the reports cited of pneumococci of South African Group V, a serotype found
with a frequency only slightly less than that of Group T.
In November 1974, in the course ofthe field trials of pneumococcal vaccine being
conducted then in South Africa [18], an attempt was made to locate strains of
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pneumococci in groups classified by Lister which had never had their correlates in
the contemporary nomenclatures of capsular types established. This search was un-
successful; but, in the repository of Dr. Ordman's biological reagents at the South
African Institute for Medical Research, several sealed ampuls of pneumococcus
Group V antiserum were discovered. Two ampuls were taken to the University of
Pennsylvania, and the serum was tested systematically with the Quellung reaction
against a variety of pneumococcal capsular types. It reacted strongly, despite the
fact that it was several decades old, with strains of pneumococcus type 46 in the
Danish classification, type 73 in the American scheme. This observation was com-
patible with Eddy's findings but not with those of Lund, who found Ordman's type
T to correspond with Danish type 46.
In 1976, two of Ordman's pneumococcal strains were obtained from Dr. Eddy,
who wrote as follows: "The T strain (same as my Type 72) was marked JK: the other
culture (same as my type 73) was marked 108E." Strain JK is indeed a strain of type
72 in the American classification (type 45 in the Danish), and strain 108E reacts both
with antiserum to capsular type 73 in the American (type46 in the Danish) classifica-
tion and with Ordman's antiserum to capsular Group V. It would appear that,
somewhere in the interchange of strains among the laboratories in Africa, Europe,
and North America, a strain was mislabeled; and it may never be possible to deter-
mine with certainty the identity of Lister's pneumococci in Groups T and V. It is
most likely, however, that they are represented by types 45 and 46 in the con-
temporary Danish classification and that type 45 represents Group T and type 46
Group V.
Nearly four decades after Ordman's reconciliation of the South African
nomenclature of pneumococcal groups with Cooper's classification of capsular
types, pneumococci in Groups T and V, which will be referred to hereafter respec-
tively as types 45 and 46 in the Danish nomenclature, were still prevalent in popula-
tions of Southern African gold miners. Among 575 isolates from respiratory secre-
tions and/or blood of patients with radiologically confirmed pneumonia or
bacteremia, 63 (11 percent) were type 46 and 14 (2.4 percent) were type 45. Among
189 strains isolated from blood cultures, there were 17 (9 percent) each of types 45
and 46, placing both among the five types most frequently causing bacteremia. Most
ofthe individuals from whom these isolates were obtained were young adult African
males from Mozambique or Malawi. None had received pneumococcal vaccine.
Pneumococcal types 45 and 46 are uncommon in most other parts ofthe world in
which studies have been done, although both have been recognized in Papua-New
Guinea where type 46 was responsible in one area for 29 (25 percent) of 115
bacteremic infections [19]. In the United States, there were only two isolates of type
45 and three of type 46 among 4,335 pneumococcal strains recovered from blood
cultures in the past two decades [20]. Whether or not there is agenetic predisposition
to infection with these two pneumococcal types in certain ethnic groups in Southern
Africa and in Papua-New Guinea is unknown, although a relationship between
human genotype and susceptibility to infection with certain capsulated bacteria has
been suggested, but not established, by several groups of investigators [21,22]. The
structure of the capsular polysaccharides of pneumococcal types 45 [23] and 46 [24]
has each been established recently, information which may be helpful in understand-
ing ultimately their infectivity, and both polymers have been incorporated in ex-
perimental vaccines. The work begun by Lister and his associates 70 years ago in
South Africa continues to bear fruit.
177178 ROBERT AUSTRIAN
ACKNOWLEDGEMENT
The author expresses his appreciation to the South African Institute for Medical Research and to Drs.
J.H.S. Gear, H.J. Koornhof, and C.H. Wyndham for their assistance in locating and making
pneumococcal Group V antiserum available.
REFERENCES
1. Bezancon F, Griffon V: Pouvoir agglutinatif du serum dans les infections experimentales et hu-
maines a pneumocoques (deuxieme partie). Compte Rendu Hebdom. Seances et MWm de la Soc de
Biologie 49:579-581, 1897
2. Neufeld F, Handel L: Weitere Untersuchungen uber Pneumokokken-Heilsera. III. Mitteilung. Uber
Vorkommen und Bedeutung atypischer Vareitaten der Pneumokokkus. Arb a d Kaiser Ge-
sundhtsamte 34:293-304, 1910
3. White B: The Biology of Pneumococcus. Cambridge, Harvard University Press, 1979, pp 103-118
4. Heffron R: Pneumonia with Special Reference to Pneumococcus Lobar Pneumonia. Cambridge,
Harvard University-Press, 1979, pp 22-24; p 947
5. Austrian R: Of gold and pneumococci. A history of pneumococcal vaccines in South Africa. Trans
Amer Clin Climat Assoc 89:141-161, 1977
6. Obituary: Sir Frederick Spencer Lister. S Afr Med J 13:685-687, 1939
7. Lister FS: Specific serological reactions with pneumococci from different sources. Pub S Afr Inst
Med Res 1(2):103-116, 1913
8. Lister FS: An experimental study of prophylactic inoculation against pneumococcal infection in the
rabbit and in man. Pub S Afr Inst Med Res 1(8):231-287, 1916
9. Lister FS: Prophylactic inoculation of man against pneumococcal infections, and more particularly
against lobar pneumonia. Pub S Afr Inst Med Res 1(10):304-322, 1917
10. Ordman D: Pneumonia in the native mine workers on the Witwatersrand goldfields. J Med Assoc S
Afr 5:108-116, 1931
11. Lister S, Ordman D: The epidemiology of pneumonia on the Witwatersrand goldfields and the
prevention of pneumonia and other allied acute respiratory diseases in native labourers in South
Africa by means of vaccine. Pub S Afr Inst Med Res 7:1-81, 1935
12. Cooper G, Rosenstein C, Walter A. et al: The further separation of types among the pneumococci
hitherto included in Group IV and the development of therapeutic antisera for these types. J Exp
Med 55:531-554, 1932
13. Austrian R: The Quellung reaction, a neglected microbiologic technique. Mt Sinai J Med
43:699-709, 1976
14. Ordman D: Pneumococcus types in South Africa. A study of their occurrence and distribution in the
population and the effect thereon of prophylactic inoculation. Pub S Afr Inst Med Res 9:1-27, 1938
15. Eddy BE: Nomenclature of pneumococcic types. Pub Health Rep 59:449-451, 1944
16. Lund E: Four new pneumococcus types. Acta Path Microbiol Scand 27:720-725, 1950
17. Lund E: The present status ofthe pneumococci, including three new pneumococcus types. Acta Path
Microbiol Scand 40:425-435, 1957
18. Austrian R, Douglas RM, Schiffman G, et al: Prevention of pneumococcal pneumonia by vaccina-
tion. Trans Assoc Amer Phys 89:184-194, 1976
19. Riley ID: Pneumonia in Papua New Guinea. Thesis for the degree of Doctor of Medicine, the
University of Sydney, 1979, pp 111-117
20. Austrian R: Unpublished observations
21. Whisnant JK, Rogentine GM, Gralnick MA, et al: Host factors and antibody response to
Haemophilus influenzae type b meningitis and epiglottitis. J Infect Dis 133:448-455, 1976
22. Pandey JP, Virella G, Loadhold CB, et al: Association between immunoglobulin allotypes and im-
mune responses to Haemophilus influenzae and meningococcus polysaccharides. Lancet i:190-192,
1979
23. Daoust V, Carlo DJ, Zeltner JY, et al: Specific capsular polysaccharide of type 45 Streptococcus
pneumoniae (American type 72). Infect Immun 32:1028-1033, 1981
24. Benzing L, Carlo DJ, Perry MB: Specific capsular polysaccharide of type 46 Streptococcus
pneumoniae. Infect Immun 32:1024-1027, 1981